• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by NuCana plc

    3/18/25 4:12:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCNA alert in real time by email
    6-K 1 d905011d6k.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

    For the month of March 2025

    (Commission File No. 001-38215)

     

     

    NUCANA PLC

    (Translation of registrant’s name into English)

     

     

    3 Lochside Way

    Edinburgh EH12 9DT

    United Kingdom

    (Address of registrant’s principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F ☒   Form  40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):  ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):  ☐

     

     

     


    Other Events

    On March 18, 2025, NuCana plc (the “Company”) distributed a notice of its general meeting to be held on April 7, 2025 (the “GM”) and a form of proxy to its ordinary shareholders. The notice of the GM, including the explanatory notes providing an explanation to the resolutions being put to shareholders, is attached as Exhibit 99.1 hereto.

    The purpose of the GM is for the Company’s ordinary shareholders to consider and vote upon, and if thought fit, pass and approve the following resolutions:

     

      1.

    As an ordinary resolution, that, in accordance with section 618 of the Companies Act 2006 (the “Act”) and subject to the passing of Resolution 3 below, each of the 151,923,897 ordinary shares of £0.04 each in the issued share capital of the Company be and is sub-divided into and redesignated as (i) 1 ordinary share of £0.0004, having the same rights and being subject to the same restrictions (except as to nominal value) as the existing ordinary shares in the capital of the Company, as set out in the Company’s articles of association from time to time and (ii) 99 deferred shares of £0.0004 each, having the rights and being subject to the restrictions set out in the Company’s articles of association (to be adopted pursuant to Resolution 3 below and thereafter as amended and adopted from time to time), such that, following the passing of this resolution, the Company’s issued share capital shall be comprised of 151,923,897 ordinary shares and 15,040,465,803 deferred shares, in each case, of £0.0004 each.

     

      2.

    As an ordinary resolution, that, subject to the passing of Resolution 1, the Board of Directors of the Company (the “Directors”) be generally and unconditionally authorized pursuant to Section 551 of the Act to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of £20,000,000. This authority shall, unless previously renewed, revoked or varied by the Company in general meeting, expire on June 30, 2026 or, if earlier, the conclusion of the annual general meeting of the Company to be held in 2026, save that the Company may, at any time before such expiry, make any offer or agreement which would or might require rights to subscribe for or to convert securities into shares to be granted or equity securities to be allotted after the authority expires, and the Directors may allot shares or grant such rights in pursuance of such offer or agreement as if the authority had not expired. This resolution revokes and replaces all unexercised authorities previously granted to the Directors to allot shares or grant rights to subscribe for or convert securities into shares but without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authorities.

     

      3.

    As a special resolution, that, subject to the passing of Resolution 1, the new articles of association of the Company in the form annexed to these resolutions be adopted as the articles of association of the Company in substitution for, and to the entire exclusion of, the existing articles of association of the Company.

     

      4.

    As a special resolution, that, subject to the passing of Resolution 2, the Directors be empowered pursuant to Section 570 of the Act to allot equity securities (as defined in Section 560(1) of the Act) for cash under the authority given by that resolution as if Section 561(1) of the Act did not apply to any such allotment, provided that such authority shall be limited to the allotment of equity securities up to a nominal amount of £20,000,000, such authority to expire on June 30, 2026 or, if earlier, the conclusion of the annual general meeting of the Company to be held in 2026, but prior to its expiry the Company may make offers, and enter into agreements, which would, or might, require equity securities to be allotted after the authority expires and the Directors may allot equity securities under any such offer or agreement as if the authority had not expired.

    On or about March 18, 2025, Citibank, N.A., in its capacity as the depositary bank (the “Depositary”) for the Company’s American Depositary Shares (“ADSs”), commenced mailing notice materials and voting cards to ADS holders to enable ADS holders of record as of March 11, 2025 to instruct the Depositary to vote the ordinary shares represented by their ADSs. If the Depositary receives timely voting instructions from an ADS holder, it will endeavor to vote the ordinary shares (in person or by proxy) represented by the holder’s ADSs in accordance with the ADS holder’s voting instructions. The ability of the Depositary to carry out voting instructions may be limited by practical and legal limitations and ADS holders may not receive voting materials in time to enable them to return voting instructions to the Depositary in a timely manner. The notice materials to be mailed by the Depositary to ADS holders will contain a link to the Company’s website where ADS holders can view and download the GM notice distributed by the Company to its ordinary shareholders (which contains explanatory notes for the resolutions being voted on at the GM).


    The information in this report on Form 6-K is being furnished and the notice of the GM, including the explanatory notes providing an explanation to the resolutions being put to shareholders is being furnished in this report on Form 6-K as Exhibit 99.1 and neither shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

    Exhibits

     

    Exhibit   

    Description

    99.1    Notice of Annual General Meeting


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    NuCana plc
    By:  

    /s/ Hugh S. Griffith

    Name:   Hugh S. Griffith
    Title:   Chief Executive Officer

    Date: March 18, 2025

    Get the next $NCNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NCNA

    DatePrice TargetRatingAnalyst
    8/30/2024Outperform → Mkt Perform
    William Blair
    3/3/2022Outperform → Market Perform
    Cowen & Co.
    11/24/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NCNA
    SEC Filings

    View All

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    1/6/26 8:11:52 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    12/17/25 8:12:19 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    12/10/25 8:15:43 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

    Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced financial results for the third quarter ended September 30, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We recently announced promising data for both NUC-7738 and NUC-3373 that continue to support the potential of our ProTides to deliver

    11/13/25 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

    EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced that the China National Intellectual Property Administration ("CNIPA") has granted an important patent covering the composition of matter for NUC-7738.   This patent (ZL 202010794701.2) is expected to serve as a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition of matter patent covers the chemical structure of NUC-7738, NuCana's novel anti-cancer agent currently being evaluated in a Phase 1/2 clinical study (NuTide:701) in combination with pembrolizumab for patients with PD-1 inhibitor re

    11/5/25 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NuCana downgraded by William Blair

    William Blair downgraded NuCana from Outperform to Mkt Perform

    8/30/24 7:44:58 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana downgraded by Cowen & Co.

    Cowen & Co. downgraded NuCana from Outperform to Market Perform

    3/3/22 6:12:40 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on NuCana with a new price target

    HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously

    11/24/21 6:13:12 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

    EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized

    11/1/21 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

    EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and

    8/10/21 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NuCana plc

    SC 13G/A - NuCana plc (0001709626) (Subject)

    10/4/24 10:14:46 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by NuCana plc (Amendment)

    SC 13D/A - NuCana plc (0001709626) (Subject)

    2/27/24 4:29:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NuCana plc (Amendment)

    SC 13G/A - NuCana plc (0001709626) (Subject)

    2/14/24 4:26:01 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care